Source: Eur Respir J 2014; 43: 1201-1203
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Burgel Pierre-Régis, Deslée Gaetan, Jebrak Gilles, Brinchault Graziella, Caillaud Denis, Chanez Pascal, Court-Fortune Isabelle, Escamilla Roger, Nesme-Meyer Pascale, Paillasseur Jean-Louis, Perez Thierry, Roche Nicolas. Real-life use of inhaled corticosteroids in COPD patients versus the GOLD proposals: a paradigm shift in GOLD 2011?. Eur Respir J 2014; 43: 1201-1203

Member's Comments

No comment yet.

Related content which might interest you: Treatment with inhaled corticosteroids in COPD groups GOLD A and B –relationship to clinical state in the COSYCONET cohort Source: Virtual Congress 2021 – Treatments for airway diseases Year: 2021 Impact of the GOLD 2011 guidelines on treatment regimens in COPD patients Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections Year: 2015 Efficacy of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) on exacerbations and health status in GOLD Group D COPD patients: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Effect of aclidinium bromide on dyspnoea and health status in patients with stable COPD: Phase III data by GOLD 2013 classification Source: International Congress 2014 – Asthma and COPD management Year: 2014 2 years in the life of COPD patients: Evolution of GOLD 2011 classification in the ’real-life’ DACCORD study Source: International Congress 2016 – Comorbidities and exacerbations in COPD Year: 2016 High risk COPD patients cost less if treated according to GOLD 2011 recommendations Source: Annual Congress 2013 –COPD diagnosis Year: 2013 COPD: GOLD 2011 and implications for clinical practice Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders Year: 2013 The same COPD patients, different GOLD criteria – what are the consequences of changing GOLD 2007-2011-2017 recommendations? Source: International Congress 2018 – Epidemiology of COPD : from exarcebations and comorbidities to asthma-COPD overlap syndrome (ACOS) Year: 2018 Efficacy of aclidinium bromide in patients with stable COPD: Pooled analysis of phase III data by GOLD 2013 criteria Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 GOLD BCD or 234 classifications: Which one better reflects COPD patients' functionality? Source: International Congress 2014 – Physical activity, exercise and physiotherapy in patients with COPD Year: 2014 Once-daily QVA149 improves lung function and health status versus twice-daily salmeterol/fluticasone (SFC) in symptomatic GOLD B and GOLD D COPD patients: LANTERN/ILLUMINATE pooled analysis Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 GOLD 2017 versus GOLD 2011 - comparison of the risk of exacerbations and mortality in COPD patients Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD? Year: 2018 Treatment with inhaled corticosteroids (ICS) in patients with COPD: possible way of optimisation Source: Annual Congress 2009 - Drug effects in COPD Year: 2009 The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Eligibility of patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections Year: 2015 The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Hospital adherence to GOLD guidelines for COPD exacerbation. Results of the European CODP audit Source: Annual Congress 2013 –Guidelines and exacerbations Year: 2013 Glycopyrronium (GLY) and tiotropium (TIO) comparison: Lung function, dyspnea and health status in COPD patients in all GOLD groups Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 The patient’s role in the choice of new inhaler devices and dosing regimens for asthma and COPD: A preference study Source: International Congress 2016 – Kaleidoscope of respiratory nursing Year: 2016 Evaluation of the GOLD 2011 severity criteria across the COPD spectrum Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations Year: 2013